Biocad receives bevacizumab biosimilar approval in Russia

December 10, 2015 7:16 AM

A Russian biopharmaceutical company Biocad obtained a marketing authorization for the bevacizumab biosimilar in Russia.

The Russian MoH has approved the new medicine on November 25, 2105.

Bevacizumab is one of the most expensive therapeutic proteins reimbursed by the Russian government, and is included in the federal list of essential drugs, which regulates pricing strategy in the domestic market and determines the maximal cost of medicinal products.

In Russia the official registered price for 400 mg of the originator product by F. Hoffmann-La Roche Ltd, is RUR 61 536 without the VAT.  Biocad’s product will be 30 % less expensive and will be available at the price RUR 43 075. Patients in Russia will have access to the new biosimilar by Q1 2016.

Biocad’s pricing strategy for bevacizumab biosimilar opens up a new perspective for reconsidering the cost/benefit ratio of anti-vascular endothelial growth factor (VEGF) therapy and increases the access to the medicine.

Biocad press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!